Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

RELATED NEWS
Trade ACT now with 
3/14/2012 4:43 PM ET

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI: Quote), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

Click here to receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Justin Moore has been named Humanitarian of the Year by by the Armed Forces Foundation. Moore received the award alongside Big Machine Label Group President/CEO Scott Borchetta for their service and commitment to the morale and welfare of military families through the Crown Royal "Your Hero's Name Here" contest. International Business Machines Corp. said Wednesday after the markets closed that its first quarter profit fell 21% from last year, hurt by lower revenue as well as a hefty workforce rebalancing charge. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks moved sharply higher over the course of the trading day on Wednesday, further offsetting the steep losses posted late last week. The markets benefited from a positive reaction to the latest earnings news as well as remarks by Federal Reserve Chairman Janet Yellen. The major averages saw further upside going into the close, ending the session at their best levels of the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.